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Abstract
Background: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which
recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the
therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic
inflammation and compared any such effect with anti-IL-5 treatment.
Methods: OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100
µg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was
given 50 µg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were
subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled
using 5-bromo-2'-deoxyuridine (BrdU). BrdU+ eosinophils and CD34+ cell numbers were examined
by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular
staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow
Cytometry. The Mann-Whitney U-test was used to determine significant differences between
groups.
Results: Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly
produced (BrdU+) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil
counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all
tissue compartments, as well as BrdU+ eosinophils and CD34+ progenitor cells, and in all instances
to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone
marrow CD4+ cells after allergen exposure.
Conclusions: Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to
reduce allergen-induced influx of newly produced cells from bone marrow to airways. However,
in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may
participate in the regulation of granulocytopoiesis in allergic inflammation.
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Background
Airway eosinophilic inflammation is a predominant fea-
ture of asthma. Eosinophils are believed to be involved in
several features of asthma through the release of cationic
granule proteins, reactive oxygen radicals, a variety of
cytokines and bronchoconstrictive mediators [1-4]. The
regulation of the eosinophil in asthma is considered to be
orchestrated by the Th2-cell, which can release a range of
Th2-cytokines, particularly interleukin (IL)-5 [5-8]. These
cytokines regulate eosinophil growth, differentiation and
activation.
IL-9 is another Th2-derived cytokine with pleiotropic bio-
logical effects on various types of cells. It acts as a growth
factor for T cells, a maturation factor for B cells, and as a
proliferation and differentiation factor for mast cells and
hematopoietic progenitors [9-13]. Recently, it has been
suggested that IL-9 might play a role in allergy [14-22].
Evidence from both murine and human mapping studies
shows that IL-9 is a candidate gene for asthma [17,18].
Moreover, the expression of IL-9 and its receptor is
increased in allergic asthma [19-21]. It was also shown
that eosinophils have the capacity to synthesize and
release IL-9 [23]. Evidence, that in vitro, IL-9 prolongs eosi-
nophil survival, as well as IL-5 mediated differentiation
and maturation [24,25], suggests that IL-9 may potentiate
eosinophil function in vivo. In vivo, locally instilled IL-9
increases eosinophil count in BAL fluid [16]. Moreover,
IL-9 transgenic mice were found to display significantly
enhanced eosinophilic inflammation [15]. Eosinophils
develop from CD34+ progenitor cells, and it has been sug-
gested that IL-9 alone may upregulate the expression of IL-
5 Rα  on human CD34+ cord blood progenitor cells [24].
Despite increasing evidence, that IL-9 may be involved in
allergy, only few studies have been performed using an IL-
9 antagonist to test its possible therapeutic efficacy in the
treatment of allergic inflammation. Furthermore, the pos-
sible regulatory effect of IL-9 on newly produced eosi-
nophils and CD34+  progenitor cells has not been
documented. In our study, we aimed to examine the effect
of a neutralizing monoclonal anti-IL-9 antibody on differ-
ent tissue compartments in vivo, in a model of allergic
eosinophilic inflammation, and relate this effect to newly
produced eosinophils (labelled with 5-bromo-2'-deoxyu-
ridine; BrdU) and CD34+ cells. Furthermore, we com-
pared the effect of anti-IL-9 with that of anti-IL-5.
Methods
Animals
Male Balb/c mice, 5 to 6 weeks old, were obtained from
B&K Universal AB (Sollentuna, Sweden). All animals were
maintained under conventional animal housing condi-
tions and provided with food and water ad libitum. The
experimental protocol was approved by the Animal Ethics
Committee in Gothenburg, Sweden.
Sensitization and allergen exposure protocol
All mice were sensitized by intraperitoneal (i.p.) injection
with 8 µg of ovalbumin (OVA; Sigma-Aldrich Sweden AB,
Tyresö, Sweden) adsorbed to 4 mg of aluminum hydrox-
ide (Al(OH)3; Sigma) in 0.5 ml of phosphate-buffered
saline (PBS). A booster dose of the OVA-Al(OH)3 mixture
was given on a second occasion, five days after the first
injection. Starting eight days after the second sensitiza-
tion, the animals were briefly anesthetized using aero-
solized Isoflurane (Baxter, Deerfield, Ill), and exposed to
100 µg OVA in 25 µl of PBS by intranasal (i.n.) adminis-
tration on five consecutive days.
Pretreatment with anti-cytokine antibodies and treatment 
with BrdU
Animals were pretreated i.p. with a single dose (100 µg/
animal) of purified hamster anti-mouse IL-9 monoclonal
antibody (clone D9302C12; Pharmingen, San Diego, CA,
USA) or its isotype control, purified hamster IgG (clone
G235-2356; Pharmingen). In parallel groups, animals
were treated either with a single dose (50 µg/animal) of a
monoclonal antibody to mouse IL-5 (clone TRFK-5; R&D
Systems Europe Ltd., Barton Lane, Abingdon, UK) or its
isotype control, rat IgG1 (clone R3-34; Pharmingen) in 0.5
ml of PBS, 30 min. before the OVA exposure. Secondly,
the combined treatment of anti-IL-9 and anti-IL-5 anti-
bodies was tested. Animals were treated with both anti-IL-
9 (100 µg/animal) and anti-IL-5 (50 µg/animal), either
anti-IL-9 (100 µg/animal) and rat IgG1 (50 µg/animal), or
anti-IL-5 (50 µg/animal) and purified hamster IgG (100
µg/animal), or both isotype controls together (100 µg of
purified hamster IgG and 50 µg of rat IgG1). Newly pro-
duced inflammatory cells were labelled with a thymidine
analogue, 5'-bromo-2'-deoxyuridine (BrdU; Boehringer
Mannheim Scandinavia AB, Bromma, Sweden), at a dose
of 1 mg in 0.25 ml of PBS i.p. twice (7 h apart) on day one
and three of allergen exposure (total dose 4 mg/animal).
Cell collection and samples processing
Samples were collected 24 h after the last allergen expo-
sure. The animals were anesthetized with an i.p. mixture
of xylazine (130 mg/kg) and ketamine (670 mg/kg).
When in adequately deep anaesthesia, the chest was
opened and samples of blood, bronchoalveolar lavage
fluid (BALf) and bone marrow were taken.
Blood was obtained by penetration of the right ventricle
of the heart with a needle. BAL was performed through the
trachea with a cannula by instillation of 0.25 and 0.2 ml
of ice-cold PBS. BALf of each animal was pooled; approx-
imately 0.4 ml of the instilled fluid was consistently recov-
ered. Finally, one femur was excised and cut at theRespiratory Research 2005, 6:33 http://respiratory-research.com/content/6/1/33
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epiphyses. Bone marrow cells were removed by perfusion
of the femur with 2 ml of PBS. BALf and bone marrow cell
suspension were kept on ice until further processing.
Cytospin of blood was obtained by taking 200 µl of blood
and mixing it with 800 µl 2 mM EDTA (Sigma) in PBS.
The red blood cells were lysed in 0.1% potassium bicarbo-
nate and 0.83% ammonium chloride for 15 min. at 4°C
as described previously [8]. The white blood cells were re-
suspended in PBS with 0.03% bovine serum albumin
(BSA; Sigma). Serum was obtained from the remaining
volume of blood by centrifugation at 3000 rpm for 10
min. at 4°C.
BAL and bone marrow cell suspension were centrifuged at
1000 rpm for 10 min. at 4°C. Supernatants were aspirated
and cells were re-suspend in PBS with 0.03% BSA. The
total number of cells in BAL, bone marrow and blood was
determined using standard hematological procedures.
Cytospins of BALf, bone marrow and blood cells were pre-
pared and stained with May-Grünwald-Giemsa for differ-
ential cell counts. Cell differentiation was determined by
counting 300–400 cells using a light microscope (Zeiss
Axioplan 2; Carl Zeiss, Jena, Germany). The cells were
identified by standard morphological criteria, and bone
marrow mature and immature eosinophils were deter-
mined by nuclear morphology, May-Grünwald-Giemsa
staining properties, and cytoplasmic granulation, as previ-
ously described [7,8]. Cytospin preparations for immuno-
cytochemistry were air-dried and stored at -80°C until
further examination.
Immunocytochemical detection of BrdU-labelled 
eosinophils
Intranuclear BrdU was detected in BAL, bone marrow and
blood cytospins using a mouse monoclonal antibody
against BrdU. Cytospin preparations taken out of the
freezer were fixed overnight in 4% paraformaldehyde, and
subsequently washed with tris-buffer saline (TBS) and
subjected to digestion in trypsin (No.232-650-8; Sigma)
diluted in distillated H2O at 37°C for 20 min. The slides
were then incubated in 4 M HCl for 15 min. to denature
the DNA, followed by neutralization in Holmes Borate-
Borax buffer (1.24% H3BO3 in distillated H2O, pH 8.5)
for 10 min. The samples were treated with peroxidase
blocking solution (No. S2023; DAKO) for 1 h. Non-spe-
cific binding sites were blocked with 5% normal rabbit
serum (No. X0902; DAKO) for 15 min. Subsequently, the
slides were incubated with 2.5 µg/ml rat anti-BrdU anti-
body (clone BU1/75; No. MAS 250p; Harlan-Sera Lab) or
isotype control, rat IgG2a (clone R35-95; Pharmingen) in
incubation buffer (0.5% BSA/TBS) for 1 h. After washing
in 0.05% Tween/TBS and TBS, the slides were incubated
with 1:50 dilution of rabbit F(ab')2  anti-rat Ig-HRP
(No.6130-05, SBA) and 2% normal mouse serum
(No.X0910; DAKO) for 1 hour. After further washing, the
staining with DAB substrate-chromogen system (No.
K3466; DAKO) was developed for 10–15 min. by moni-
toring in microscope. The slides were counterstained with
Mayer's hematoxylin for 30 sec. and eosin for 2 min.,
dehydrated and mounted in Mountex. All slides were
evaluated on light microscope in random fields of view.
Cells with any nuclear brown staining together with the
pink staining in cytoplasma were counted as BrdU-
labelled (BrdU+) eosinophils.
Immunocytochemical detection of CD34+ progenitor cells
Cytospin preparations from blood, BAL and bone marrow
were fixed in 2% formaldehyde for 10 min. All incuba-
tions were performed at room temperature (RT). After
washing in TBS, endogenous biotin was blocked with
DAKO Biotin Blocking system. The preparations were
incubated with a monoclonal biotinylated rat anti-mouse
CD34 antibody (0.5 µg/ml; clone RAM34, BD Bio-
sciences) or its isotype control (biotinylated Rat IgG2a, BD
Biosiences) for 2 h. After further washings, the prepara-
tions were incubated with Streptavidin Alkaline-Phos-
phatase (DAKO) for 45 min. Bound antibodies were
visualized with Vector Red Alkaline Phosphatase Sub-
strate kit (Vector Laboratories Inc. Burlingame, CA, USA).
The preparations were washed in Tris-HCl buffer (100
mM, pH 8.2–8.5), rinsed in distilled H2O and counter-
stained with Mayer's hematoxylin for 30 sec., dehydrated
and mounted in Mountex. Three hundred cells were
counted in random fields of view.
Measurement of IL-5 and IL-9
IL-5 concentration in serum and BALf from anti-IL-9 or its
control treated animals was measured using a commercial
murine IL-5 enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Inc, Abingdon, UK) according
to the manufacturer's instruction. The detection limit for
IL-5 was 5 pg/ml.
Quantification of IL-9 was measured in BALf, serum and
fresh bone marrow supernatant (the femur was perfused
twice with 1 ml of PBS) from OVA-sensitized and exposed
for 5 days to OVA or PBS (control) animals by ELISA
method. ELISA plate (Maxisorp F96, NUNC) was incu-
bated with 100 µl of purified rat anti-mouse IL-9 antibody
(No.551218, BD) at a concentration of 1 µg/ml in coating
buffer (0.1 M NaHCO3, pH 9.5) at 4°C for 18 h. All incu-
bations were performed in dark. After washings with PBS
containing 0.05% Tween 20, non-specific bindings were
blocked with assay diluent (10% fetal calf serum, FCS, in
PBS) for 1 h at RT. After further washings, bone marrow
supernatant, BALf and serum samples (100 µl of each)
were incubated in duplicate at 4°C for 18 h. A standard
curve was generated by using serial dilutions of recom-
binant mouse IL-9 (No.551867, BD). After washing, 100Respiratory Research 2005, 6:33 http://respiratory-research.com/content/6/1/33
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µl of biotinylated anti-mouse IL-9 antibody (No. 554473,
BD) at a concentration 0.5 µg/ml in the assay diluent was
added and incubated at RT for 1 h. After further washings,
the plates were incubated with 1:6000 dilution of Extr-
Avidin HRP (No. E2886, Sigma) for 30 min. After another
washing, 100 µl of TMB substrate solution was added and
incubated for 30 min. The reaction was terminated by
adding 50 µl of stop solution (1.0 M H2SO4) and assessed
with an ELISA reader (type-349; Labsystems, Stockholm,
Sweden) at 450 nm. The detection limit for IL-9 was 125
pg/ml.
Culture of bone marrow cells
Bone marrow cells were harvested from OVA-sensitized
and exposed for six days animals, after 4 h of the last expo-
sure. Cells were cultured in a 48-well plate in RPMI 1640
culture medium, complemented with 10% FCS, 1% peni-
cillin-streptomycin, 1% sodium pyruvate and 2 mM L-
glutamine (all obtained from Sigma) in a concentration of
1 × 106 cells/500 µl of medium at 37°C in an atmosphere
containing 5% CO2. Cells were cultured only with plain
medium (for negative control), either stimulated with 100
µg/ml of OVA or stimulated with phorbol myristate ace-
tate (PMA) and calcium ionophore (end conc. 2 ng/ml
and 1 µg/ml respectively, both obtained from Sigma).
After 2 h, Brefeldin A solution was added in a final con-
centration of 10 µg/ml, and incubated for additional 6 h.
FACS analysis of bone marrow cells for IL-9 intracellular 
staining
After incubation, bone marrow cells were harvested,
washed and double-stained (CD4 surface/ IL-9 intracellu-
lar), using a standard saponin protocol [26] with some
modifications. Unspecific binding was blocked with 2%
mouse sera (Dako) for 15 min. The cells were thereafter
incubated with a phycoerythrin-conjugated anti-CD4
(clone H129.19, Pharmingen) and its isotype-matched
control for 30 min. at 4°C. Surface immunostained cells
were fixed in 4% paraformaldehyde at room temperature
for 10 min., followed two washings in 1% FCS/PBS. After
resuspention in 2 ml of SAP Buffer (0.1% saponin and
0.05 NaN3, w/v in HBSS, Sigma), the cells were incubated
with a biotin-conjugated anti-mouse IL-9 monoclonal
antibody (clone D9302C12, Pharmingen) at RT for 40
min., then with streptavidin-FITC for 20 min. Finally, the
cells were washed with 1% FCS/PBS, resuspended in the
same Buffer, and analyzed using a FACScan flow cytome-
ter (Becton Dickinson, Mountain View, CA). Ten thou-
sand cells were computed in a list mode and analyzed
using the CellQuest Software (Becton Dickinson).
Statistics
Results are presented as mean values ± SEMs. The Mann-
Whitney  U-test was employed for comparison of data
between groups. Value of p < 0.05 was considered as sta-
tistically significant.
Results
Cellular changes in BAL
Total cell numbers in BAL were not different between anti-
IL-9 and its control IgG treated groups (Figure 1a). There
was no significant difference in eosinophil, neutrophil,
and lymphocyte numbers in BAL. Animals treated with
anti-IL-9 had significantly higher number of macrophages
in BAL (Figure 1a) and significantly lower percentage of
eosinophils in comparison to its control treated animals
(63.4 ± 6.7 vs 80.1 ± 1.4 % of total cells in BAL, p = 0.024).
Anti-IL-5, in comparison to control IgG1 treated mice, sig-
nificantly decreased the total cell number in BAL, mainly
due to decrease in eosinophil number (Figure 1b).
Immunocytochemical stainings of BAL cells for BrdU and
CD34 are illustrated in Figure 2. Anti-IL-9 did not signifi-
cantly change newly produced (BrdU+) eosinophil num-
bers in BAL (Figure 3a), but decreased the percentage of
BrdU- eosinophils in BAL (11.5 ± 1.4 vs 16.6 ± 1.5 % of
total cells in BAL, p = 0.024). The number of BrdU+ BAL
eosinophils was extensively reduced by anti-IL-5 (Figure
3b).
Anti-IL-9 did not affect the increase in BAL CD34+ granu-
locytes induced by OVA-exposure, but slightly (p = 0.048)
decreased the number of BAL CD34- granulocytes (Figure
4a). Numbers of BAL CD34+ and CD34- granulocytes were
significantly reduced with anti-IL-5 treatment (Figure 4b).
Blood cells
As compared with the control antibody, treatment with
anti-IL-9 significantly decreased the number of blood
neutrophils, but without effect on other cell types or total
blood cell numbers (Figure 5a). Anti-IL-5 treatment sig-
nificantly decreased blood eosinophil number (Figure
5b).
Immunocytochemical analysis of intranuclear BrdU stain-
ing in blood cells showed significant decrease in BrdU+
eosinophils from animals treated with anti-IL-9, com-
pared to its control treated animals (Figure 6a). Also anti-
IL-9 significantly reduced the number of BrdU+ blood
neutrophils (0.7 ± 0.1 vs 1.3 ± 0.2 × 106/ml blood, p <
0.05). Treatment with anti-IL-5 decreased BrdU+  and
BrdU- blood eosinophil numbers (Figure 6b), without any
effect on BrdU+ blood neutrophils.
Anti-IL-9 treatment and anti-IL-5 treatment did not signif-
icantly affect allergen induced increase in total blood
CD34+ cell numbers (data not shown).Respiratory Research 2005, 6:33 http://respiratory-research.com/content/6/1/33
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Cellular profiles of BAL-cells in OVA-sensitized and on five days exposed to OVA Balb/c mice Figure 1
Cellular profiles of BAL-cells in OVA-sensitized and on five days exposed to OVA Balb/c mice. Animals were pretreated with 
a) anti-IL-9 antibody or its isotype control IgG (100 µg/animal); or with b) anti-IL-5 antibody or its isotype control IgG1 (50 µg/
animal) 30 minutes before the first exposure. BAL was performed 24 hours after the last OVA-exposure. Data are shown as 
mean ± SEM (n = 5–10 per group). *p < 0.05 compared with the corresponding isotype control antibody (Mann-Whitney U 
test).
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Bone marrow eosinophils and CD34+ cells
Anti-IL-9 treatment reduced bone marrow eosinophilia
with significant effect on mature eosinophils (Figure 7a).
Anti-IL-5 treatment decreased mature and immature bone
marrow eosinophils (Figure 7b).
Anti-IL-9 also decreased BrdU+  eosinophil number in
bone marrow, but did not affect BrdU- eosinophils (Figure
8a). Anti-IL-5 treatment reduced both BrdU+ and BrdU-
eosinophils in bone marrow (Figure 8b).
Anti-IL-9 treatment did not significantly change bone
marrow CD34+ cell numbers, as compared with control
treated animals (p = 0.08). Anti-IL-5 significantly reduced
CD34+ cell numbers in bone marrow, as compared with
its isotype control treatment (26.7 ± 2.7 vs 16.5 ± 2.7 % of
total cells, p = 0.03).
Effect of anti-IL-9 treatment on IL-5
Anti-IL-9 treatment, as compared to its isotype control
treatment, did not significantly change IL-5 levels in
serum (8.7 ± 2.3 vs 30.5 ± 16.7 pg/ml respectively, p =
0.24) and BALf (20.8 ± 6.2 vs 54.6 ± 22.2 pg/ml respec-
tively, p = 0.16).
IL-9 production in bone marrow cells after repeated 
allergen exposure
The concentration of IL-9, measured by ELISA, in bone
marrow supernatant from allergen-exposed animals was
369 ± 247 pg/ml, but was not detectable in serum and
Photomicrographs (original magnification: ×1000) of BAL cells immunocytochemical analysis of staining positively for BrdU  (brown nuclear, a) and CD34 (red, b) in sensitized and exposed to OVA on five consecutive days mice Figure 2
Photomicrographs (original magnification: ×1000) of BAL cells immunocytochemical analysis of staining positively for BrdU 
(brown nuclear, a) and CD34 (red, b) in sensitized and exposed to OVA on five consecutive days mice. a) 1- BrdU+ eosinophil, 
2- BrdU- eosinophil, 3- BrdU+ neutrophil. b) 1- CD34+ granulocyte, 2- CD34- granulocyte.Respiratory Research 2005, 6:33 http://respiratory-research.com/content/6/1/33
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BALf from the same animals, as well as in PBS-exposed
animals. IL-5 in bone marrow supernatant from the same
animals was not detectable by ELISA.
Flow cytometry, using intracellular staining of IL-9,
revealed that bone marrow cells from sensitized and OVA-
exposed for six days animals after in vitro stimulation with
OVA and PMA together with calcium ionophore (IC), had
increased expression of IL-9 in comparison with baseline
(1.04 and 1.84 times fold respectively). This expression
was more pronounced in the bone marrow CD4+ cells
(Figure 9). There was no substantial difference between
the percent of bone marrow cells expressing CD4 at base-
line (plain medium), or after stimulation with OVA, or
PMA+IC (9.1%, 8.5% and 6.2% respectively).
Effects of combination of anti-IL-5 and anti-IL-9
The effects of combined treatment with anti-IL-5 and anti-
IL-9 are described in Table I. No additive effect of anti-IL-
9 was observed above the effect of anti-IL-5.
Discussion
Our study was designed to determine whether treatment
with a monoclonal anti-IL-9 antibody affects the allergic
inflammation in a mouse model of airway eosinophilic
inflammation and compared any such effect with the
Effect of treatment with the neutralizing antibodies on BAL eosinophils stained positive for BrdU and unstained cells in OVA- sensitized and on five days exposed to OVA Balb/c mice Figure 3
Effect of treatment with the neutralizing antibodies on BAL eosinophils stained positive for BrdU and unstained cells in OVA-
sensitized and on five days exposed to OVA Balb/c mice. BrdU was injected on first and third day of OVA exposure period. 
Animals were pretreated with a) anti-IL-9 antibody or its isotype control IgG (100 µg/animal); or with b) anti-IL-5 antibody or 
its isotype control IgG1 (50 µg/animal) 30 minutes before the first exposure. Data are shown as mean ± SEM (n = 5–10 per 
group). **p < 0.01 compared with the corresponding isotype control antibody (Mann-Whitney U test).
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results of anti-IL-5 antibody treatment. The monoclonal
anti-IL-9 antibody, given at a dose of 100 µg before aller-
gen exposure, did not significantly reduce allergen-
induced airway eosinophilia, but consistently reduced
bone marrow eosinophilia, by a reduction of newly pro-
duced (BrdU+) and mature bone marrow eosinophils. IL-
9 was expressed in bone marrow CD4+ cells after allergen
exposure, which was more pronounced after stimulation
of the cells with allergen or PMA+IC. The monoclonal IL-
5 antibody, given at a dose of 50 µg before allergen expo-
sure, reduced eosinophil numbers in all tissue compart-
ments, as well as BrdU+  eosinophils and CD34+
progenitor cells. The effect of anti-IL-5 was significantly
greater than the effect of anti-IL-9, and no additive effect
of anti-IL-9 was observed beyond the effect of anti-IL-5.
In our study, the neutralizing anti-IL-9 antibody treatment
was given as a single dose administered intraperitoneally
in sensitized animals before the allergen exposure.
Despite variable effects of IL-9 in in vitro studies of allergic
cellular processes [23-25], the treatment with a neutraliz-
ing anti-IL-9 antibody in vivo in our study did not protect
airways from the abundant eosinophilia in BAL, arguing
against anti-IL-9 having a potential as an anti-inflamma-
tory treatment in established allergic disease. This result is
in contrast with a previous report by Cheng and
Effect of treatment with the neutralizing antibodies on allergen-induced changes of BAL granulocytes stained for CD34 in Balb/ c mice (sensitized and on five days exposed to OVA) Figure 4
Effect of treatment with the neutralizing antibodies on allergen-induced changes of BAL granulocytes stained for CD34 in Balb/
c mice (sensitized and on five days exposed to OVA). Animals were pretreated with a) anti-IL-9 antibody or its isotype control 
IgG (100 µg/animal); or with b) anti-IL-5 antibody or its isotype control IgG1 (50 µg/animal) 30 minutes before the first expo-
sure. Data are shown as mean ± SEM (n = 5–10 per group). **p < 0.01 compared with the corresponding isotype control anti-
body (Mann-Whitney U test).
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Blood cellular profiles in OVA-sensitized and on five days exposed to OVA Balb/c mice Figure 5
Blood cellular profiles in OVA-sensitized and on five days exposed to OVA Balb/c mice. Animals were pretreated with a) anti-
IL-9 antibody or its isotype control IgG (100 µg/animal); or with b) anti-IL-5 antibody or its isotype control IgG1 (50 µg/animal) 
30 minutes before the first exposure. Blood was taken 24 hours after the last OVA-exposure. Data are shown as mean ± SEM 
(n = 5–10 per group). *p < 0.05, **p < 0.01 compared with the corresponding isotype control antibody (Mann-Whitney U 
test).
Total cells Neutrophils Eosinophils Monocytes Lymphocytes
Control IgG
Anti-IL-9
B
l
o
o
d
c
e
l
l
s
(
x
1
0
6
/
m
l
)
*
0
1
2
3
4
0
1
2
3
4
5
Total cells Neutrophils Eosinophils Monocytes Lymphocytes
B
l
o
o
d
c
e
l
l
s
(
x
1
0
6
/
m
l
)
Control IgG1
Anti-IL-5
**
a)
b)Respiratory Research 2005, 6:33 http://respiratory-research.com/content/6/1/33
Page 10 of 15
(page number not for citation purposes)
colleagues [27], which showed that a polyclonal anti-IL-9
antibody at a dose of 20 µg significantly inhibited airway
eosinophilic inflammation. The fact that the antibody
used in that study was polyclonal may suggest that the
inhibitory effect was not solely dependent on inhibition
of IL-9. Treatment with a monoclonal anti-IL-9-antibody
during the sensitization process attenuates the develop-
ment of airway allergic inflammation and airway hyperre-
sponsiveness in mice exposed to allergen at a later time,
implying a role of IL-9 in the development of allergy [28].
However, the treatment was given in very high concentra-
tion (200 µg) as four doses (total 800 µg/animal) during
the sensitization period, which would correspond to very
high doses of antibody treatment in a clinical situation.
Furthermore, clinical treatment of allergic disease is given
to individuals that have already been sensitized to one or
several allergens, why any effect of a neutralizing antibody
during sensitization is unlikely to be helpful clinically.
Importantly, our finding of no or limited inhibitory effect
of BAL eosinophilia by anti-IL-9 is in agreement with a
report showing that sensitized IL-9KO mice [29] respond
with normal airway inflammation after allergen exposure.
Despite the lack of effect of inhibition of airway eosi-
nophilia by anti-IL-9, we consistently observed an inhibi-
tory effect of the treatment on the increase in bone
Changes of BrdU-staining in blood eosinophils in sensitized and exposed to allergen (OVA; 100 µg intranasally on five consec- utive days) Balb/c mice after the treatment with a) anti-IL-9 antibody or its isotype control IgG (100 µg/animal); or with b) anti- IL-5 antibody or its isotype control IgG1 (50 µg/animal) 30 minutes before the first exposure Figure 6
Changes of BrdU-staining in blood eosinophils in sensitized and exposed to allergen (OVA; 100 µg intranasally on five consec-
utive days) Balb/c mice after the treatment with a) anti-IL-9 antibody or its isotype control IgG (100 µg/animal); or with b) anti-
IL-5 antibody or its isotype control IgG1 (50 µg/animal) 30 minutes before the first exposure. BrdU was injected on first and 
third day of OVA exposure period. Data are shown as mean ± SEM (n = 5–10 per group). *p < 0.05 compared with the corre-
sponding isotype control antibody (Mann-Whitney U test).
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marrow eosinophils after allergen exposure. Airway aller-
gic inflammation is to a great extent the result of the
recruitment of newly produced cells from bone marrow
via blood under the influence of allergen. Newly pro-
duced eosinophils, labeled with BrdU, to a substantial
degree contribute to the allergen-induced inflammatory
process, which results in an accumulation of eosinophils
in the airways [7,8,30]. Anti-IL-9 treatment significantly
decreased the number of mature eosinophils in bone mar-
row, and reduced newly produced eosinophils (BrdU+) in
bone marrow as well as in blood. This supports the
hypothesis that IL-9 participates in the eosinophilopoiesis
and the release of eosinophils from bone marrow to
blood. However, the regulatory effect of IL-9 seems to be
of a subordinate magnitude compared to IL-5, since the
effects induced by neutralization of IL-5 were of a much
greater magnitude.
Eosinophils develop from CD34+ progenitor cells that
undergo terminal differentiation normally within the
bone marrow and primarily under the influence of IL-5,
but also with the support of other cytokines. In several
animal studies, an increase in the CD34+ population is
observed in the bone marrow, circulation and airways
after the allergen exposure [7,8,30,31], as well as in
human studies of atopic subjects, regardless of asthmatic
Effect of treatment with the neutralizing antibodies on bone marrow (BM) eosinophil content profiles in OVA-sensitized and  on five days exposed to OVA Balb/c mice Figure 7
Effect of treatment with the neutralizing antibodies on bone marrow (BM) eosinophil content profiles in OVA-sensitized and 
on five days exposed to OVA Balb/c mice. Animals were pretreated with a) anti-IL-9 antibody or its isotype control IgG (100 
µg/animal); or with b) anti-IL-5 antibody or its isotype control IgG1 (50 µg/animal) 30 minutes before the first exposure. Figure 
shows both eosin-staining cells with immature and with mature morphology. Data are shown as mean ± SEM (n = 5–10 per 
group). *p < 0.05, **p < 0.01 compared with the corresponding isotype control antibody (Mann-Whitney U test).
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status [32,33]. In vitro IL-9 has shown a capacity to act on
hematopoietic progenitors to enhance eosinophil
development when added to CD34+ cells cultured with a
mixture of IL-3 and IL-5 [12,13]. In our study in vivo, we
failed to observe any effect of anti-IL-9 on CD34+ cells,
and no significant effects were observed on IL-5 levels
either in serum or in BALf. However, the anti-IL-5 anti-
body showed pronounced capacity to reduce an allergen-
induced increase in CD34+ cells in both bone marrow and
BAL. Again, our data therefore suggest that IL-9 has a sub-
ordinate role compared to IL-5 in eosinophilopoiesis.
Lymphocytes, especially circulating lymphocytes, are con-
sidered to be the major cellular source of IL-9 [19]. We
found that bone marrow CD4+ cells taken from allergen-
exposed animals, over-expressed IL-9 after in vitro stimu-
lation with OVA or PMA and calcium ionophore. This
finding further supports a role of IL-9 in allergen-induced
bone marrow responses, especially in enhanced
granulocytopoiesis, although the degree of the response
and the exact importance remain to be elucidated.
We also found some degree of reduction of blood neu-
trophils after allergen exposure in animals treated with
anti-IL-9. Primarily, a reduction of BrdU+ neutrophils was
observed, which may imply a role of IL-9 in the produc-
tion of neutrophils in the bone marrow. This study was
not designed to specifically evaluate the role of IL-9 in
BrdU-staining in bone marrow (BM) eosinophils in OVA-sensitized and on five days exposed to OVA Balb/c mice Figure 8
BrdU-staining in bone marrow (BM) eosinophils in OVA-sensitized and on five days exposed to OVA Balb/c mice. BrdU was 
injected on first and third day of OVA exposure period. Animals were pretreated with a) anti-IL-9 antibody or its isotype con-
trol IgG (100 µg/animal); or with b) anti-IL-5 antibody or its isotype control IgG1 (50 µg/animal) 30 minutes before the first 
exposure. Data are shown as mean ± SEM (n = 5–10 per group). *p < 0.05, **p < 0.01 compared with the corresponding iso-
type control antibody (Mann-Whitney U test).
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neutrophilia, but implies that such studies may be of
interest. This is further supported by the finding that IL-9
can induce IL-8 production in a concentration depend
manner [34].
We cannot exclude the possibility that even higher doses
of the neutralizing monoclonal IL-9 antibody could have
been more effective in attenuating eosinophilia. Overall,
however, the degree of contribution of IL-9 in allergen-
induced airway eosinophilia seems to be much smaller
than that of IL-5, since the treatment with the single dose
of the anti-IL-5 antibody (50 µg) significantly inhibited
bone marrow, blood and airway eosinophilia, but the
higher dose of anti-IL-9 (100 µg) was much less effective.
Furthermore, the fact that IL-9KO mice respond with sim-
ilar degree of inflammation after sensitization and aller-
gen exposure as wild type mice [29] further supports a
subordinate role of IL-9 in allergen induced airway
eosinophilia.
Taken together, our data indicate that IL-9 may have some
degree of regulatory effect on eosinophilia in the bone
marrow and blood, perhaps via eosinophilopoiesis, since
newly produced eosinophils were reduced in these com-
partments. However, no inhibitory effect on airway
eosinophils was observed after anti-IL-9 treatment, which
Intracellular expression of IL-9, detected by flow cytometry in the bone marrow CD4+ cells from OVA-sensitized and exposed  for 6 days animals, cultured in vitro with OVA or PMA (phorbol myristate acetate) + IC (calcium ionophore) Figure 9
Intracellular expression of IL-9, detected by flow cytometry in the bone marrow CD4+ cells from OVA-sensitized and exposed 
for 6 days animals, cultured in vitro with OVA or PMA (phorbol myristate acetate) + IC (calcium ionophore). Data are 
expressed as time-fold increase of the mean fluorescence intensity (MFI) of the baseline expression (culture with plain 
medium).
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argues that the development of such a drug will be unsuc-
cessful in treating allergic airway eosinophilia.
List of abbreviations
BAL bronchoalveolar lavage
BrdU 5-bromo-2'-deoxyuridine
IC calcium ionophore
IL interleukin
i.n. intranasal(ly)
i.p. intraperitoneal(ly)
OVA ovalbumin
PBS phosphate-buffered saline
PMA phorbol myristate acetate
RT room temperature
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